Skip to main content
. 2022 Mar 4;14(5):1316. doi: 10.3390/cancers14051316

Figure 1.

Figure 1

RHAMM and CD44 in follicular lymphoma. (A,B) Representative images of tumor tissue stained for RHAMM. (C) Area fractions of RHAMM staining in FL diagnostic samples from patients with and without subsequent HT, and in lymphoma samples from time of HT diagnosis. (D) Area fractions of RHAMM staining exclusively localized in intrafollicular areas of diagnostic FL samples from patients with and without subsequent HT. (E,F) Representative images of tumor tissue stained for CD44. (G) Area fractions of CD44 staining in FL diagnostic samples from patients with and without subsequent HT, and in lymphoma samples from time of HT diagnosis. (H) Area fractions of CD44 staining exclusively localized in intrafollicular areas of diagnostic FL samples from patients with and without subsequent HT. (I) CD44/RHAMM ratio calculated from expression of both markers in the tumor-tissue sections for patients with and without subsequent HT, and in lymphoma samples from time of HT diagnosis. (J) CD44/RHAMM ratio calculated from intrafollicular expression of both markers for patients with and without subsequent HT. Abbreviations: nt-FL, non-transforming follicular lymphoma; RHAMM, receptor of hyaluronic acid mediated motility; st-FL, subsequently-transforming follicular lymphoma; tFL, histologically transformed follicular lymphoma.